Dunno other then my one eye was stuck shut every morning for a couple of weeks when I first started iodine.
In my recent research I ran into this, no idea if it works but I saw it on a shelf and was shocked at the price. This store only keeps things that move on the limited shelf space, so I asked and was told that it sells very well.
Your mileage may vary:
From:
http://aor.ca/int/related_research/ortho_eyes.php
Eyes Syruped Shut
Misshapen proteins accumulate across the entire structure of the eye with “normal” aging, interfering with visual functioning. AGEs, in particular, play a major role in the universal age-related loss of eye structure and function, as well as in the more specific degenerative diseases of the aging eye, such as cataracts, glaucoma, and age-related macular degeneration (AMD).
Delivering Carnosine directly to the eye itself, then, would be predicted to be the ideal real-world test case for the test-tube finding that Carnosine can protect against – and perhaps even actually undo – the damage wrought by glycation and other protein-warping mechanisms of aging. New human trials have shown that topical Carnosine delivers on this promise.
• In an open study protocol, scientists gave Carnosine supplements to patients in late middle age who had varying degrees of visual impairment, but no symptomatic cataracts. Over the course of two to six months, the scientists observed that the use of topical Carnosine supplementation “appears to alleviate eye tiredness and … obviously improve eyesight, giving more clear vision.” Users found that topical Carnosine “could brighten and relax their eyes.” The improvements were statistically significant.
• In clinical studies involving 109 patients, these scientists found Carnosine effective in cases of primary and secondary corneal dystrophy, corneal erosions, trophic keratitis, and bullous keratopathy, as well as corneal ulcerations and other damage wrought on the cornea by viral and bacterial infections. The Russian government accordingly approved topical Carnosine supplementation for these uses as early as 1997.
• 21 people, with a total of 27 affected eyes, who had suffered corneal haze following Photorefractive Keratectomy (PRK – a form of laser surgery) (27 eyes were affected), were given topical Carnosine three times a day for two months. Fully 57.9% of people using the Carnosine eye drops experienced a reduction in corneal haze intensity, accompanied by an improvement in visual acuity; only 14% of users’ eyes continued to worsen. The positive results appeared in patients with low to moderate myopia, who had developed moderate haze (1 to 1.5 on a 3-point scale) within a month of surgery; there are no known treatments which are effective for late corneal haze of a higher grade than this.
• In a second, larger, and more rigorous trial, patients who had just undergone PRK (41 patients (including 73 affected eyes)) or LASIK (“LAser in-Situ Keratomileusis” – 34 people, 60 eyes) were given the same thrice-daily regimen of topical Carnosine as was used in the first trial, while corresponding control groups (41 PRK patients and 34 LASIK recipients) received Carnosine-free dummy eye drops. Compared with people applying the placebo solution, the healing of the corneal epithelium of people supplementing with Carnosine eye drops took 35 hours less time to regrow – a speeding of the epithelial re-growth process of nearly a day and a half. Even better, users of topical Carnosine supplements following LASIK were one-third less likely to suffer corneal haze than those using the un-supplemented eye drops!
• In an open investigation, 96 senior citizens who had suffered with senile cataracts for as little as two to as much as twenty-one years applied topical Carnosine supplements to their eyes three or four times a day, for periods ranging from three to six months. At the end of the study, the researchers found that Carnosine eye drops lead to improvements in eyesight and lens transparency in the great majority of patients. They saw improvements in every single one of the people suffering with early-stage cataracts; and even in mature senile cataract, a remarkable 80% of the topical Carnosine users experienced a benefit. The investigators went on to expand on these preliminary results with the sequential treatment of nearly a thousand cataract patients – to similar success and with no side effects observed.
Instead of using Carnosine itself, more recent trials have used N-acetyl-L-Carnosine, a metabolite of Carnosine, which the body slowly converts back into free Carnosine, allowing for slower, more thorough delivery of free Carnosine into the eye’s tissues and access to areas of the eye where Carnosine itself cannot penetrate.
• In a randomized, double-blind, placebo-controlled study, scientists first evaluated the baseline state of cataract victims’ eyes. The scientists then randomly handed out either topical N-Acetyl-L-Carnosine supplements (as a 1% solution) or an identical-looking placebo solution. A third group of cataract patients received no eye drops at all.
After just six months, ninety percent of the eyes of people supplementing with N-Acetyl-L-Carnosine eye drops saw their visual acuity improve, with the strength of the effect ranging from a modest gain to a full 100% recovery. In the same period, only 5.7 percent of the eyes of people using the stand-in eye drops were judged to have improved visual acuity, while over a third (34.7%) suffered a worsening of acuity, and most (60%) simply retained the same impaired vision with which they had begun the study. In a two-year extension, N-Acetyl-L-Carnosine eye drop users were shown to maintain their improved vision, while the eyesight of those not receiving the supplement continues to deteriorate.
• On top of the gains in visual acuity, researchers observed that N-Acetyl-L-Carnosine topical supplementation also clearly improves glare sensitivity, with 88.9% of N-Acetyl-L-Carnosine eye drop users’ eyes seeing improvements ranging from 27 to 100% after just six months; again, the divide separating supplementers from non-supplementers was unequivocal, with over half (56.3%) of nonusers’ eyes deteriorating and none getting any better. The glare sensitivity tests were not repeated at the two-year mark.
• At the end of the full two-year trial, the image analyses showed that 47.8% of the lenses of N-Acetyl-L-Carnosine topical supplement users were clearer than they were at the beginning of the trial – and none had worsened. Meanwhile, none of the people whose eye drops did not contain N-Acetyl-L-Carnosine showed improvements on the image analysis, while a predictable 47.4% of the lenses continuing the hazy slide into blindness.
For the first time, a simple topical treatment was proved to actually reverse the clouding of the cataracted lens – and the treatment was not a drug, but a natural substance naturally present in healthy cells.